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Abstract
Background: This study was performed to evaluate the clinical effectiveness of alternative strategies for the
prevention and treatment of patients with chronic kidney disease undergoing peritoneal dialysis and colonized
by Staphylococcus aureus.
Methods: A systematic review and meta-analysis were performed. The literature search involved the following
databases: the Cochrane Controlled Trials Register, Embase, LILACS, CINAHL, SciELO, and PubMed/Medline. The
descriptors were “Staphylococcus aureus,” “MRSA,” “MSSA,” “treatment,” “decolonization,” “nasal carrier,” “colonization,”
“chronic kidney disease,” “dialysis,” and “peritoneal dialysis.” Randomized controlled trials that exhibited agreement
among reviewers as shown by a kappa value of >0.80 were included in the study; methodological quality was
evaluated using the STROBE statement. Patients who received various antibiotic treatments (antibiotic group) or
topical mupirocin (mupirocin group) were compared with those who received either no treatment or placebo
(control group). Patients in the antibiotic group were also compared with those in the mupirocin group.
Results: In total, nine studies involving 839 patients were included in the analysis, 187 (22.3 %) of whom were
nasal carriers of S. aureus. The probability of S. aureus infection at the catheter site for peritoneal dialysis was 74 %
lower in the mupirocin than control group (odds ratio [OR], 0.26; 95 % confidence interval [CI], 0.14–0.46; p < 0.
001), 56 % lower in the antibiotic than control group (OR, 0.44; 95 % CI, 0.19–0.99; p = 0.048), and 52 % lower in
the mupirocin than antibiotic group (OR, 0.48; 95 % CI, 0.21–1.10; p = 0.084). The difference in the probability of
S. aureus peritonitis in patients undergoing peritoneal dialysis was not statistically significant among the three groups.
Conclusions: Mupirocin and topical antibiotics were effective for reduction of S. aureus catheter site infection in
patients undergoing peritoneal dialysis when compared with no treatment or placebo. However, evidence was
insufficient to identify the optimal agent, route, or duration of antibiotics to treat peritonitis.
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Background
Peritoneal dialysis (PD) is an effective form of renal re-
placement therapy in patients with end-stage chronic renal
failure. Despite recent improvements in connection tech-
nology, the development of skin infection at the catheter
exit site and peritonitis remains a major cause of morbidity,
hospitalization, catheter removal, termination of PD with
permanent transfer to hemodialysis, and even death [1].
In 2005, the International Society for Peritoneal Dialy-
sis determined that the peritonitis rate should be fewer
than 0.67 episodes per patient per year [2], and in 2011
recommended that a rate of fewer than 0.36 episodes
per year should be achieved by most programs [3]. How-
ever, rates of 0.63 to 1.66 episodes of peritonitis per pa-
tient per year and a catheter exit site infection rate of
0.72 episodes per year at risk have been reported [4, 5].
Worldwide, gram-positive cocci such as Staphylococ-
cus epidermidis, coagulase-negative Staphylococcus, and
S. aureus are the most frequent etiological agents in
peritonitis associated with PD [2]. According Barreti et
al. [6] the main causative agent of peritonitis in the
world is coagulase-negative Staphylococcus however S.
aureus is associated with the most severe episodes and
increased risks of hospitalization, death, and catheter re-
moval [7]. A rate of S. aureus peritonitis of 0.12 episodes
per patient per year has been reported [4].
Approximately 20 % of healthy people are chronic
carriers of S. aureus, 30 % are intermittent carriers, and
50 % are not susceptible to carriage for unknown
reasons [8]. An estimated 2 million individuals in the
Netherlands are chronic carriers of S. aureus based on
the prevalence rate in that country. In the United States,
an estimated 53 million people are chronic carriers of S.
aureus [8]. Aktaş et al. [9] demonstrated a clear associ-
ation between S. aureus carriage and S. aureus infection
in patients undergoing PD. Twenty-three genotypes were
established for the 28 isolates, demonstrating high clonal
heterogenecity. Six clinical isolates from four patients
undergoing hemodialysis and four clinical isolates from
two patients undergoing PD were molecularly evaluated
to compare isolates obtained from infection with the
carriage isolates of the same patients. All but one of
these clinical isolates were "indistinguishable/closely
related" to the isolates obtained from the same patients
as the carriage isolates.
Various antimicrobial agents have been used for preven-
tion of infection associated with S. aureus nasal
colonization and peritoneal catheter exit site infection in
patients with renal insufficiency. Mupirocin is an anti-
biotic that has been used locally in the nasal cavity and
skin to eradicate S. aureus colonization with good results.
Research conducted at the Federal University of São Paulo
demonstrated that the application of topical mupirocin at
the catheter insertion site significantly diminished the risk
of S. aureus colonization and infection [10]. However, the
emergence of multiresistant strains to this drug should be
considered, as shown in a study conducted in Spain. That
study revealed strains with high levels of resistance to
mupirocin that were associated with a methicillin-
resistant S. aureus (MRSA) pandemic [11].
In addition, systemic antibacterial agents such as cip-
rofloxacin, novobiocin, trimethoprim/sulfamethoxazole,
and rifampicin have also been used to eradicate
colonization by S. aureus in patients with chronic renal
failure. Among these antibiotics, rifampicin has been the
most studied drug for this purpose [12].
Collection of surveillance cultures can be used to con-
trol the spread of multidrug-resistant pathogens. Early de-
tection of patients colonized with multidrug-resistant
microorganisms can allow for effective establishment of
measures to control cross transmission. Eradication of the
S. aureus carrier state includes prevention of infection and
transmission. Several eradication strategies have been
evaluated, but studies differ significantly in their design.
To fill some gaps in this regard, we considered it im-
portant to conduct a systematic review to evaluate the
clinical effectiveness of alternative strategies for the pre-
vention and eradication of S. aureus carriage in patients
undergoing PD.
Methods
This systematic review and meta-analysis followed the
steps proposed by the Cochrane Collaboration [13] and
was performed in accordance with the PRISMA guidelines
statement for systematic review reporting [14]. The inclu-
sion criterion was S. aureus colonization in patients with
chronic kidney disease undergoing PD as the primary out-
come. The exclusion criteria were nonrandomized studies,
letters, editorials, and case reports; studies involving pa-
tients <18 years of age; evaluation of S. aureus infection
treatment outcomes without evaluation of the effect of
nasal colonization; and no specification of the therapy
administered to the treatment group. The two interven-
tions compared in this meta-analysis were prophylactic
treatment/decolonization to control cross transmission
and S. aureus infection (peritonitis and skin infection at
the catheter insertion site) between treated and untreated
patients undergoing PD.
The following characteristics of each study were
extracted: study design; total numbers of patients receiv-
ing various antibiotic treatments (antibiotic group),
mupirocin (mupirocin group), and placebo or control
(control group) with corresponding rates of eradication;
colonization by S. aureus; and peritonitis.
Study identification strategy
Relevant studies published from January 1989 to January
2014 were identified through a search of the following
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electronic databases: the Cochrane Library (including
the Cochrane Controlled Trials Register), Embase, LI-
LACS, SciELO, CINAHL, and Medline/PubMed. The prin-
cipal descriptors used in the search were “Staphylococcus
aureus,” “MRSA,” “MSSA,” “treatment,” “decolonization,”
“nasal carrier,” “colonization,” ”chronic kidney disease,”
“dialysis,” and “peritoneal dialysis.”
Study selection
The studies were read by two independent reviewers
(C.G. and M.T.) to ascertain whether they fulfilled the
inclusion criteria. The reviewers were not blinded. Each
reviewer evaluated the titles and abstracts of all identi-
fied studies and obtained complete photocopies of all
relevant articles. In cases of doubt or disagreement, a
third reviewer (D.A.B.) was solicited to issue an opinion
regarding whether the study should or should not be
included.
Evaluation of methodological quality
Methodological quality was defined as confidence that
the study design and reporting were free of bias. Two in-
dependent reviewers used the recommendations of the
Cochrane framework and the STROBE statement
(STrengthening the Reporting of OBservational studies
in Epidemiology). Based on the STROBE recommenda-
tions [13], studies included in the meta-analysis were di-
vided into three categories: (A) >80 % compliance with
the STROBE criteria, (B) 50 % to 80 % compliance with
the STROBE criteria, and (C) <50 % compliance with
the STROBE criteria (Table 1).
Data extraction and statistical analysis
The studies were initially stratified according to their de-
sign. Based on these results, they were subsequently
stratified following the Cochrane methodology. Compre-
hensive Meta-Analysis software was used for statistical
analysis. For dichotomous variables, the odds ratio (OR)
with 95 % confidence interval (CI) was calculated using
random-effects and fixed-effects models. The Mantel–
Haenszel chi-squared test and the I2 test were used to
calculate heterogeneity [15].
Results
The PRISMA flow chart in Fig. 1 summarizes the search
process. Initially, 143 articles were identified in the
PubMed/Medline database, 54 in SciELO, 32 in
Cochrane, 4 in LILACS, and 10 in Embase. Of the 243
total studies identified, 234 were excluded (36 were arti-
cles published and duplicated in different databases, 96
met the exclusion criteria, 82 did not present the princi-
pal result, 11 did not evaluate nasal colonization by S.
aureus, 5 did not report data on population control, and
4 did not report the duration of follow-up).
Thus, nine studies were evaluated: a prospective
double-blind randomized controlled trial [16] and eight
randomized clinical trials [17–24]. All studies were eval-
uated and classified as having a low risk of bias and
adequate methodological quality by the Cochrane refer-
ential [13]. Randomization of the studies included in this
review was performed by a computer, and concealment
of the allocation was adequate.
These studies involved a total of 839 individuals (420
patients in the intervention group and 419 in the control
group). Of these 839 individuals, 187 (22.3 %) were nasal
carriers of S. aureus (see Additional file 1).
Based on the STROBE recommendations [13], eight
studies were placed in category A and one study was
placed in category B. This meta-analysis did not include
studies in category C (<50 % compliance with the cri-
teria established by STROBE) (Table 1).
Different interventions were evaluated, including nasal
agents (calcium mupirocin ointment 2 % [16, 22], nasal
neomycin ointment 0.1 % [22], and sodium fusidate
[20]), topically applied antimicrobial agents in the cath-
eter exit site (calcium mupirocin ointment 2 % [17, 21,
23, 24], gentamicin sulfate 0.1 % [21], cefazolin + genta-
micin [19], and sodium fusidate [20]), and orally admin-
istered antibiotics (rifampicin 600 mg [18, 23] and
ofloxacin [20]) (Table 2).
Several therapies were compared to evaluate the infec-
tion prevention effectiveness at the exit of the PD cath-
eter and peritonitis caused by S. aureus. Mupirocin was
compared with no treatment or placebo in two studies
[16, 17]. Mupirocin was compared with gentamicin, ri-
fampicin, and neomycin in four studies [21–24]. The an-
tibiotics rifampicin, cefazolin + gentamicin, ofloxacin,
and sodium fusidate were compared with placebo or no
treatment in three studies [18–20].
The probability of skin infection at the PD catheter
exit site caused by S. aureus was 74 % lower in the
mupirocin than control group (OR, 0.26; 95 % CI, 0.14–
0.46; p < 0.001) (Fig. 2), 56 % lower in the antibiotic than
control group (OR, 0.44; 95 % CI, 0.19–0.99; p = 0.048)
Table 1 Quality of clinical trials included in the present meta-analysis
Concealment of allocation Blinded investigator Blinded participant Blinded assessor Blind data analysis Intention-to-treat Lost to follow-up
Adequate: 5 Yes: 4 Yes: 4 Yes: 3 Yes: 1 Declared: 3 Yes: 6
Inadequate: 1 No: 2 No: 1 No: 1 No: 1 Not declared: 6 No: 0
Obscure: 3 Obscure: 3 Obscure: 4 Obscure: 5 Obscure: 7 Obscure: 3
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(Fig. 3), and 52 % lower in the mupirocin than antibiotic
group (OR, 0.48; 95 % CI, 0.21–1.10; p = 0.084) (Fig. 4).
The difference in the risk of peritonitis caused by S.
aureus in patients undergoing PD was not significant
among the three groups: mupirocin versus control group
(OR, 0.68; 95 % CI, 0.37–1.24; p = 0.20) (Fig. 5),
antibiotic versus control group (OR, 1.072; 95 % CI,
0.43–2.69; p = 0.88) (Fig. 6), and mupirocin versus anti-
biotic group (OR, 0.74; 95 % CI, 0.18–3.05; p = 0.67)
(Fig. 7).
Table 2 provides the following details: author, year of
publication, study population, total number of included
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Fig. 1 PRISMA flow diagram of systematic review inclusion and exclusion process
Grothe et al. BMC Nephrology  (2016) 17:115 Page 4 of 10
Table 2 Screening and treatment of chronic renal patients colonized with S. areus on peritoneal dialysis























1996 DCR 134 133 18 24 Nasal mupirocin 2x/day
for 5 days every 4 weeks
Placebo 18 months 18 months 90 % 14 44 18 24
Wong [17] 2003 ECR 73 81 16 14 CESS mupirocin 1x/d No treatment 5 months 5 months NT 0 10 1 1
Zimmerman
[18]
1991 ECR 32 32 9 8 Oral rifampicin 300 mg
2x/d for 5d every
3 months
No treatment 10 months 12 months NT 3 12 3 5
Lye [19] 1994 ECR 41 105 3 6 Cefazolin + CESS
gentamicin
No treatment 36 months 36 months NT 2 4 2 0
Sesso [20] 1998 ECR 9 13 5 5 Nasal and CESS sodium
fusidate
No treatment 7,8 months 7,8 months 43 % 3 5 1 6
Sesso [20] 1998 ECR 13 5 5 Oral Ofloxacin (dd) No treatment 7,8 months 7,8 months 40 % 2 5 4 6
Bernardini [21] 2005 ECR 67 66 9 9 CESS mupirocin 2x/d for
5d every 3 months
CESS gentamicin 2x/d for
5d every 3 months
8 months 8 months 97 % 0 10 1 1
Fontán [22] 1993 ECR 12 10 12 10 Nasal mupirocina for 7 d Nasal neomicin for 7 d 9,5 months 9,5 months 100 % 1 1 0 1
Bernardini [23] 1996 ECR 41 41 18 18 CESS mupirocin daily Oral Rifampicin 600 mg
1x/d for 5d every
3 months
months 12 months NT 5 6 2 1
Cavdar [24] 2004 ECR 18 18 3 0 CESS mupirocin 3x/week CESS mupirocin 1x/week 6 months 6 months 83 % 0 1 0 1
Note: n number of patients, % Percentage, NCSA nasal carrier of S. aureus, CESS catheter exit site skin, DBRCT Double blind randomized controlled trial, RCT randomized clinical trial, NT not tested, ESI Catheter Exit Site













patients, number of patients colonized with S. aureus at
study entry, number of episodes of infection at the cath-
eter exit site peritoneal dialysis; and number of episodes
of peritonitis (number of episodes over total months in
patient therapy).
Discussion
The rates of nasal S. aureus colonization, skin infection
at the exit site of the PD catheter, and peritonitis were
studied in this review. The review included 839 patients
with chronic kidney disease undergoing PD, 22.3 % of
which were S. aureus nasal carriers.
Decolonization therapy may involve topical treatment by
use of drugs at the catheter exit site or systemic antibacte-
rials by oral administration of antibiotics. However, there is
no evidence to indicate what type of treatment (topical or
systemic) is most effective for such a procedure.
Topical treatments are widely used and evaluated, and
the main antimicrobial agents tested include calcium
mupirocin ointment 2 % [16, 17, 21–24], sodium fusi-
date ointment 2 % [20], cream gentamicin, neomycin
sulfate [22], and cefazolin cream [19]. We found that
topical mupirocin reduced the risk of S. aureus infection
at the exit site of the PD catheter by 74 % compared
with the control group (placebo or no treatment) (p <
0.001). Corroborating this result, it appears that
mupirocin-based topical treatment is indicated by most
guidelines of international health agencies, including the
Centers for Disease Control and Prevention (CDC) [25]
and World Health Organization (WHO) [26]. The CDC
recommends the use of topical mupirocin alone in
patients colonized only for a short period of time and
for health care professionals [25]. Conversely, the WHO
considers the use of mupirocin and/or chlorhexidine in
patients with MRSA, but does not specify the indica-
tions, contraindications, or time of use [26]. Notably, for
the National Institute of Clinical Excellence in the UK,
the use of topical antimicrobials is not indicated in any
case because there is no evidence that this practice may
reduce health care associated infections (HAIs) either
global or those caused by MRSA [27].
Another contraindication to mupirocin is bacterial resist-
ance to this agent. In cases involving a mupirocin-resistant
agent, the possibility of endogenous recolonization is high
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Mupirocin Study Group 12 0,276 0,150 0,505 -4,165 0,000
Wong 13 0,052 0,003 0,899 -2,034 0,042
0,256 0,142 0,464 -4,498 0,000
0,01 0,1 1 10 100
Favours A Favours B
Fig. 2 Mupirocin treatment versus placebo or no treatment in patients on peritoneal dialysis colonized by S. aureus: Number of patients with CESI
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Zimmerman 14 0,293 0,082 1,049 -1,887 0,059
Lye 15 0,486 0,086 2,739 -0,817 0,414
Sesso a 16 0,860 0,199 3,720 -0,202 0,840
Sesso b 16 0,565 0,106 2,997 -0,671 0,502
0,488 0,231 1,034 -1,871 0,061
0,01 0,1 1 10 100
Favours A Favours B
Fig. 3 Antibiotics treatment versus placebo or no treatment in patients undergoing peritoneal dialysis colonized by S. aureus: Number of patients
with CESI
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after 4 weeks of treatment [27]. However, resistance to
mupirocin is still considered low. In this review, we found
only one study that reported resistance to mupirocin in
one isolated case.
Gentamicin and cefazolin were used together, and this
combination provided effective results to reduce infection
rates at the exit site of the PD catheter (0.23 vs 0.09 epi-
sode per patient per year; p < 0.005) and peritonitis (0.33
vs 0.10 episodes per patient per year; p < 0.005) [19].
Fusidic acid was evaluated separately and exhibited
statistically significant results (p < 0.01) [20] for S. aureus
eradication in colonized patients. However, it is widely
contraindicated as monotherapy for decolonization and
is indicated only as a supportive treatment or enhancer
to the use of systemic rifamycin. It did not show statisti-
cally significant results in reducing MRSA infections. In-
stead, it increased the emergence of bacterial resistance,
which reinforces the idea of not using this drug alone
for eradication of S. aureus in colonized patients [27].
Only one study compared the effectiveness of nasal
neomycin sulfate ointment three times a day for 7 days
with that of nasal mupirocin ointment daily for 7 days
and reported that mupirocin is more effective than
neomycin sulfate for elimination of S. aureus nasal
colonization in patients undergoing continuous ambula-
tory PD [22].
In this meta-analysis, the antibiotic group exhibited a
56 % lower risk of S. aureus infection at the PD catheter
exit site compared with the control group (p = 0.048).
Systemic treatment alone for S. aureus eradication is
not widely used; instead, systemic treatment is generally
associated with a topical drug. This is mainly due to
concerns about the emergence of strains resistant to an-
timicrobials [27]. The main antimicrobial agents for sys-
temic use found in this study were rifamycin and
ofloxacin [18, 20]. In the main guidelines of international
agencies (the WHO, CDC, and British Society for Anti-
microbial Chemotherapy [24–26]), the systemic treat-
ment recommendation for decolonization is that the
therapeutic drug is chosen based on consultation with
medical specialists in infectious diseases and epidemiolo-
gists at hospitals.
We found that patients treated with rifampicin showed
a significant delay in the time to first infection associated
with the PD catheter (p < 0.015) and significantly fewer
infections related to the PD catheter (p < 0.001), but
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Bernardini 17 0,046 0,003 0,787 -2,125 0,034
Fontán 18 0,832 0,051 13,472 -0,130 0,897
Bernardini 19 0,873 0,314 2,427 -0,260 0,795
Cavdar 20 0,103 0,013 0,826 -2,140 0,032
0,479 0,208 1,103 -1,730 0,084
0,01 0,1 1 10 100
Favours A Favours B
Fig. 4 Treatment with mupirocin vs. antibiotics in peritoneal dialysis patients colonized with S. aureus: Number of patients CESI
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Mupirocin Study Group 12 0,663 0,358 1,227 -1,310 0,190
Wong 13 1,129 0,070 18,103 0,085 0,932
0,679 0,372 1,239 -1,260 0,208
0,01 0,1 1 10 100
Favours A Favours B
Fig. 5 Mupirocin treatment versus placebo or no treatment in patients on peritoneal dialysis colonized by S. aureus: Number of patients
with peritonitis
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rifampicin was associated with toxicity and side effects.
Two studies reported treatment interruption due to tox-
icity in 6.6 % to 12.0 % of patients; however, no irrevers-
ible toxicity was observed, perhaps because of the short
duration of treatment used in the studies, which may
not have been long enough to cause significant clinical
interactions [18, 23].
Another systemic medication used was oral ofloxacin,
which was found in only one study and compared with the
use of topical sodium fusidate ointment. Oral ofloxacin
was less effective in the eradication of nasal colonization
and reduction of infection at the PD catheter exit site, and
both treatments showed no effect in reducing episodes of
peritonitis [20].
This meta-analysis has shown that the use of topical
antibiotics reduces the incidence of PD catheter exit site
infection, but not the incidence of peritonitis. This may
simply be a power problem (exit site infections being
much more common than peritonitis, plus the relatively
small numbers of patients involved), but raises the ques-
tion about the relationships among carriage, infection,
and peritonitis. It is likely that infection is introduced
mainly at exchange via contamination of the catheter tip
rather than tracking along the tunnel. A better technique
might reduce the risk. Our findings are similar to those
of the Cochrane Review by Strippoli et al. [15], who also
concluded that nasal mupirocin reduces exit site and
tunnel infections, but not peritonitis. The European
Guidelines [28] state that the “use of mupirocin or gen-
tamicin cream at the exit site is recommended to reduce
exit site infections,” but cites no evidence that this re-
duces peritonitis. Like the other guidelines, the authors
had to extrapolate from reduction in exit site infections
to reduction in peritonitis.
This review and meta-analysis had some limitations.
The included studies had a short follow-up and did not
allow for analysis of long-term treatment, which may
have substantially different efficacy and safety than
shown in the present results. Additionally, heterogeneity
was present between the treatments applied, and it is
not possible to conclude the best strategy for the use of
these antibiotics. Moreover, local protocols and patient
education interventions for the prevention of infection
were not analyzed in this study.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Zimmerman 14 1,202 0,241 5,996 0,224 0,823
Lye 15 5,136 0,242 108,808 1,050 0,294
Sesso a 16 0,229 0,027 1,950 -1,348 0,178
Sesso b 16 0,960 0,261 3,534 -0,062 0,951
0,927 0,386 2,227 -0,170 0,865
0,01 0,1 1 10 100
Favours A Favours B
Fig. 6 Antibiotic treatment versus placebo or no treatment in patients on peritoneal dialysis colonized by S. aureus: Number of patients
with peritonitis
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Bernardini 17 0,985 0,061 15,790 -0,011 0,992
Fontán 18 0,275 0,011 6,831 -0,787 0,431
Bernardini 19 1,336 0,297 6,001 0,378 0,705
1,002 0,295 3,400 0,003 0,997
0,01 0,1 1 10 100
Favours A Favours B
Fig. 7 Treatment with mupirocin versus antibiotics in peritoneal dialysis patients colonized with S. aureus: Number of patients with peritonitis
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Because patients often become recolonized with S.
aureus after receiving an initial treatment regimen, regu-
lar examinations with mupirocin application seems to be
a reasonable option. Meticulous attention to infection
control practices during insertion and access of the PD
catheter is also of paramount importance in the preven-
tion of S. aureus infection.
Future longitudinal studies need to define a mupirocin
regimen that balances a reduction in the incidence of S.
aureus infection with concerns about the emergence of
mupirocin resistance.
Conclusion
Peritonitis is the main cause of the need to change PD
to hemodialysis, which reduces patients’ quality of life
and increases costs to the national health system. Unfor-
tunately, the current evidence base for the prevention of
peritonitis is not supported. Nasal, oral, and local inter-
ventions reduce infections at the exit site of the PD
catheter, but not peritonitis. However, this finding may
be due to testing very small numbers of patients and for
very short periods or because the incidence of peritonitis
was low.
This meta-analysis supports the use of local antibiotics
at the catheter exit site in patients undergoing PD. How-
ever, the available data are very limited, and more stud-
ies are needed to examine the clinical importance of
antibiotics at the catheter exit site in patients undergo-
ing PD.
Additional file
Additional file 1: PRISMA checklist. (DOC 63 kb)
Abbreviations
CI, confidence interval; MRSA, methicillin-resistant S. aureus; MSSA,
methicillin-sensível S. aureus; OR, odds ratio; PD, peritoneal dialysis; PRISMA,
guidelines statement for systematic review reporting; S. aureus, Staphylococcus
aureus; STROBE, strengthening the reporting of observational studies in
epidemiology
Acknowledgements
The authors acknowledge the São Paulo State Research Foundation (FAPESP)
for its financial support of this study.
Funding
The authors received funding only from government agency FAPESP –
Fundação de Amparo à Pesquisa do Estado de São Paulo, a state research
support foundation. No funding was received from commercial source.
Availability of data and materials
All data supporting these findings can be found in the following electronic
databases: the Cochrane Library (including the Cochrane Controlled Trials
Register), Embase, LILACS, SciELO, CINAHL, and Medline/PubMed.
Authors’ contributions
CG was the principal researcher and participated in all steps of the study:
development of the project, data collection, revision of the database, data
analysis, and drafting and revision of the article. MT participated in development
of the project, data analysis and article revision. AB participated in revision of the
database and revision of the article. RS helped to compose and revise the article.
DAB coordinated and conceived of the study and participated in the project
design, supervision of data collection, data analysis, and drafting and revision of
the article. All of the authors read and approved the final version of the article.
Author’s information
CG: Nurse, PhD, and postdoctoral student (EPE/UNIFESP)
MT: Nurse, MSc, PhD, and postdoctoral student (EPE/UNIFESP)
DF: Nurse, MSc, and PhD
MFPO: Nurse, MSc, and PhD
RS: Physician, MD, PhD, and Associate Professor (EPM/UNIFESP)
DB: Nurse, PhD, MSc, and Associate Professor Associado (EPE/UNIFESP)
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
Not applicable.
Author details
1Paulista School of Nursing, Federal University of São Paulo - EPE/UNIFESP, R.
Napoleão de Barros 754, São Paulo 04024-002, Brazil. 2Division of
Nephrology, Paulista School of Medicine, Federal University of São Paulo -
EPM/UNIFESP), R. Botucatu 740, São Paulo 04023-900, Brazil.
Received: 28 April 2015 Accepted: 21 June 2016
References
1. Pignatari A, Pfaller M, Hollis R, Sesso R, Leme I, Herwaldt L. Staphylococcus
aureus colonization and infection in patients on continuous ambulatory
peritoneal dialysis. J Clin Microbiol. 1990;28(9):1898–902.
2. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, ISPD Ad
Hoc Advisory Committee, et al. Peritoneal dialysis-related infections
recommendations: 2005 update. Perit Dial Int. 2005;25:107–31.
3. Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al.
ISPD position statement on reducing the risks of peritoneal dialysis-related
infections. Perit Dial Int. 2011;31:614–30.
4. Figueiredo AE, Figueiredo CEP, Meneghetti F, Lise GAP, Detofoli CC, Silva LB.
Peritonites em pacientes em diálise peritoneal: análise de um único centro
brasileiro segundo a Sociedade Internacional de Diálise Peritoneal. J Bras
Nefrol. 2013;35(3):214.
5. Cleper R, Davidovits M, Kovalski Y, Samsonov D, Amir J, Krause I. Peritonitis
in a pediatric dialysis unit: local profile and implications. Isr Med Assoc J.
2010;12:348–52.
6. Barretti P, Bastos KA, Dominguez J, Caramori JC. Peritonitis in Latin America.
Perit Dial Int. 2007;27:332–9.
7. Grothe C, Belasco AG, Bittencourt AR, Vianna LA, Sesso R, Barbosa DA.
Incidence of bloodstream infection among patients on hemodialysis by
central venous catheter. Rev Lat Am Enfermagem. 2010;18(1):73–80.
8. Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of 404
Staphylococcus aureus bacteremia. Study Group. 2001;344(1):11–6.
9. Aktaş E, Pazarli O, Külah C, Cömert F, Külah E, Sümbüloğlu V. Determination
of Staphylococcus aureus carriage in hemodialysis and peritoneal dialysis
patients and evaluation of the clonal relationship between carriage and
clinical isolates. Am J Infect Control. 2011;39:421–5.
10. Barbosa DA, Dalboni M, Leme I, Rabello T, Pignatari AC, Sesso R.
Staphylococcus aureus nasal carrier state in CAPD patients - a four years
study. In: Mollby R, Flock JI, Nord CE, Christensson B, editors. Staphylococci
and Staphylococcal infection. New York: Gustav Fischer Verlag;
1994. p. 159–61.
11. Moore C, Dhaliwal J, Tong A, Eden S, Wigston C, Willey B, McGeer A. Risk
factors for methicillin-resistant Staphylococcus aureus (MRSA) acquisition in
roommate contacts of patients colonized or infected with MRSA in an
acute-care hospital. Infect Control Hosp Epidemiol. 2008;29:600–6.
12. Zimmerman SW, Johnson CA. Rifampin use in peritoneal dialysis. Perit Dial
Int. 1989;9(4):241-3.
13. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of
intervention. Chichester (UK): John Wiley & Sons; 2005.
Grothe et al. BMC Nephrology  (2016) 17:115 Page 9 of 10
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting
itms for systematic reviews and meta-analyses: the PRISMA statement.
J Clin Epidemiol. 2009;62:1006–12.
15. Rev Man Analyses (RevMan) [computer software] Version 1.0 for Windows,
in Review Manager 5.1. Oxford: The Cochrane Collaboration; 2005.
16. The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus
aureus exit-site infection during peri- toneal dialysis. J Am Soc Nephrol.
1996;7:2403–8.
17. Wong SSH, Chu K-H, Cheuk A, Tsang WK, Fung SKS, Chan HWH, et al.
Prophylaxis against Gram-positive organisms causing exit-site infection
and peritonitis in continuous ambulatory peritoneal dialysis patients by
applying mupirocin ointment at the catheter exit site. Perit Dial Int.
2003;23 Suppl 2:S153–8.
18. Zimmerman S, Ahrens E, Johnson C, Craig W, Leggett J, O’Brien M, et al.
Randomized controlled trial of pro- phylactic rifampin for peritoneal
dialysis-related in- fections. Am J Kidney Dis. 1991;18(2):225-31.
19. Lye WC, Leong SO, van der Straaten J, Lee EJ. Staphylococcus aureus
CAPD-related infections are associated with nasal carriage. Adv Perit Dial.
1994;10:163–5.
20. Sesso R, Barbosa D, Leme I, Sader H, Canziani ME, Manfredi S, et al.
Staphylococcus aureus prophylaxis in hemodialysis patients using central
venous catheter: effect of mupirocin ointment. J Am Soc Nephrol. 1998;9(6):
1085–92.
21. Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, et al.
Randomized, double-blind trial of antibiotic exit site cream for prevention
of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol.
2005;16:539–45.
22. Perez-Fontan M, Garcia-Falcon T, Rosales M, et al. Treatment of Staph-
ylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis
with mupirocin: long-term results. Am J Kid Dis. 1993;22:708–12.
23. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of
Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin
calcium ointment 2 % applied to the exit site versus cyclic oral rifampin.
Am J Kidney Dis. 1996;27:695–700.
24. Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z, et al. The effects of
once- or thrice-weekly mupirocin application on mupirocin resistance in
patients on continuous ambulatory peritoneal dialysis – first 6 months’
experience. Adv Perit Dial. 2004;20:62–6.
25. Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H,
Mallaghan, Tucker DR. Guidelines for the control and prevention of
meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities.
J Hosp Infect. 2006;63 Suppl 1:S1-44.
26. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE.
Guidelines for the prophylaxis and treatment of methicillin-resistant
Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob
Chemotherapy. 2006. [Acesso 23 Mar 2010]. Disponível em: http://jac.
oxfordjournals.org/content/57/4/589.short.
27. National Institute for Health and Clinical Excellence. Surgical site infection:
prevention and treatment of surgical site infection. London (UK): NIHCE;
2008.
28. Krediet RT. European best practice guidelines on peritoneal dialysis.
Nephrol Dial Transplant. 2005;20(Suppl 9):ix8-ix12.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Grothe et al. BMC Nephrology  (2016) 17:115 Page 10 of 10
